Recent Finacing
Recent Raise
RECORNA Biotechnology develops RNA‑editing oligonucleotide therapeutics that recruit endogenous ADAR to repair protein sequences without genomic changes, focusing on preclinical neurological programs and broader cardio/respiratory/aging pipelines.
Focus Areas
Recent Investors
Funding round
Investors
